NASDAQ:IOVA

Iovance Biotherapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy IOVA

*Your capital is at risk

$4.44

+0.380 (+9.36%)

At Close: Jun 23, 2026

Iovance Biotherapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 82.39. In total, the insiders bought 2.66M and sold 300.08K IOVA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	82.39
● Buy	2.66M shares
● Sell	300.08K shares
72% Buy Activity Moderate Negative Correlation
Buy Signal Medium Confidence Jun 16, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 82.39. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 16, 2026 Buy	Deferred Restricted Stock Unit A-Award	Maynard Ryan D Director	Director	90 316 Value: $345.0K
Jun 16, 2026 Buy	Deferred Restricted Stock Unit A-Award	Weiser Michael Director	Director	90 316 Value: $345.0K
Jun 16, 2026 Buy	Deferred Restricted Stock Unit A-Award	Dukes Iain D. Director	Director	180 632 Value: $690.0K
Jun 16, 2026 Buy	Deferred Restricted Stock Unit A-Award	Countouriotis Athena Director	Director	90 316 Value: $345.0K
Jun 16, 2026 Buy	Restricted Stock Units A-Award	Puri Raj K. Chief Regulatory Officer	Officer	15 000 Value: $57.3K
Jun 05, 2026 Buy	Restricted Stock Units M-Exempt	Puri Raj K. Chief Regulatory Officer	Officer	9 766 Value: $41.3K
Jun 05, 2026 Buy	Common Stock M-Exempt	Puri Raj K. Chief Regulatory Officer	Officer	9 766 Value: $41.3K
Jun 05, 2026 Buy	Common Stock M-Exempt	Graf Finckenstein Friedrich Chief Medical Officer	Officer	7 813 Value: $33.0K
Jun 05, 2026 Sell	Common Stock F-InKind	Vogt Frederick G Interim CEO & General Counsel	CEO / President	6 638 Value: $28.1K
Jun 05, 2026 Buy	Common Stock M-Exempt	Vogt Frederick G Interim CEO & General Counsel	CEO / President	15 625 Value: $66.1K
Jun 05, 2026 Buy	Restricted Stock Units M-Exempt	Vogt Frederick G Interim CEO & General Counsel	CEO / President	15 625 Value: $66.1K
Jun 05, 2026 Sell	Common Stock F-InKind	Graf Finckenstein Friedrich Chief Medical Officer	Officer	3 976 Value: $16.8K
Jun 05, 2026 Buy	Restricted Stock Units M-Exempt	Graf Finckenstein Friedrich Chief Medical Officer	Officer	7 813 Value: $33.0K
Jun 05, 2026 Sell	Common Stock F-InKind	Puri Raj K. Chief Regulatory Officer	Officer	3 843 Value: $16.3K
Jun 05, 2026 Buy	Common Stock M-Exempt	Bilinsky Igor Chief Operating Officer	C-Suite Officer	7 813 Value: $33.0K
Jun 05, 2026 Sell	Common Stock F-InKind	Bilinsky Igor Chief Operating Officer	C-Suite Officer	3 976 Value: $16.8K
Jun 05, 2026 Buy	Restricted Stock Units M-Exempt	Bilinsky Igor Chief Operating Officer	C-Suite Officer	7 813 Value: $33.0K
Jun 01, 2026 Buy	Restricted Stock Units M-Exempt	Bilinsky Igor Chief Operating Officer	C-Suite Officer	8 790 Value: $34.8K
Jun 01, 2026 Sell	Common Stock F-InKind	Bilinsky Igor Chief Operating Officer	C-Suite Officer	4 473 Value: $17.7K
Jun 01, 2026 Buy	Common Stock M-Exempt	Bilinsky Igor Chief Operating Officer	C-Suite Officer	8 790 Value: $34.8K
Jun 01, 2026 Buy	Restricted Stock Units M-Exempt	Graf Finckenstein Friedrich Chief Medical Officer	Officer	8 790 Value: $34.8K
Jun 01, 2026 Sell	Common Stock F-InKind	Puri Raj K. Chief Regulatory Officer	Officer	2 508 Value: $10K
Jun 01, 2026 Buy	Common Stock M-Exempt	Puri Raj K. Chief Regulatory Officer	Officer	5 469 Value: $21.7K
Jun 01, 2026 Buy	Restricted Stock Units M-Exempt	Vogt Frederick G Interim CEO & General Counsel	CEO / President	41 668 Value: $165.0K
Jun 01, 2026 Buy	Common Stock M-Exempt	Vogt Frederick G Interim CEO & General Counsel	CEO / President	41 668 Value: $165.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT IOVANCE BIOTHERAPEUTICS, INC.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or pers...

Read Full Profile Here